International Multiple Sclerosis Genetics Consortium

International Multiple Sclerosis Genetics Consortium
Name	International Multiple Sclerosis Genetics Consortium
Abbreviation	IMGC
Formation	2003
Type	Research consortium
Headquarters	International
Fields	Genetics, Neuroscience, Immunology

Contents

International Multiple Sclerosis Genetics Consortium

The International Multiple Sclerosis Genetics Consortium is a global research collaboration focused on the genetic architecture of Multiple sclerosis through large-scale genotyping, meta-analysis, and functional follow-up. The consortium brings together investigators from institutions such as the University of Cambridge, Harvard University, University of Oxford, Stanford University, and the Karolinska Institutet, integrating datasets from cohorts in regions including United States, United Kingdom, Sweden, Germany, and Canada to map risk loci and inform translational research.

History

The consortium emerged in the early 2000s following advances at centers like the Wellcome Trust Sanger Institute and projects such as the Human Genome Project, with foundational meetings attended by investigators from the International HapMap Project and the 1000 Genomes Project. Early milestones included genome-wide association study (GWAS) initiatives that paralleled efforts at the Broad Institute and collaborations with clinical groups at Mayo Clinic and Johns Hopkins University. Key historical collaborations involved researchers affiliated with the National Institutes of Health, the European Molecular Biology Laboratory, and the Max Planck Society as the consortium scaled to include data partners from the Australian National University and the University of Melbourne.

Membership spans academic centers such as Columbia University, University of California, San Francisco, Yale University, University of Toronto, and McGill University, alongside disease registries like the Swedish National Patient Register and biobanks including the UK Biobank and the Estonian Biobank. Governance comprises steering committees drawing expertise from clinicians at Massachusetts General Hospital and basic scientists from the ETH Zurich and the University of Geneva. Working groups coordinate with genotype facilities at the Sanger Institute, statistical genetics teams at the Institute for Molecular Medicine Finland (FIMM), and bioinformatics groups at the European Bioinformatics Institute.

The consortium’s research agenda emphasizes GWAS led by consortia such as the International HapMap Project and fine-mapping efforts inspired by the ENCODE Project and the Roadmap Epigenomics Project. Major projects include meta-analyses comparable to those from the Psychiatric Genomics Consortium and integrative analyses that leverage expression quantitative trait loci datasets from the Genotype-Tissue Expression Project and single-cell atlases like the Human Cell Atlas. The consortium pursues cross-ancestry studies involving cohorts from Japan, China, Brazil, South Africa, and India to address population stratification issues noted in work from the 1000 Genomes Project and the HapMap Project.

Published outputs include identification of risk loci overlapping immune genes previously implicated by studies at the National Institute of Allergy and Infectious Diseases and pathway analyses that resonated with findings from the Wellcome Trust consortia. Landmark papers reported associations in the major histocompatibility complex region, echoing immunogenetics work at the Fred Hutchinson Cancer Research Center and the Pasteur Institute. Subsequent publications integrated chromatin interaction maps from the ENCODE Project and functional follow-up using CRISPR methods championed by teams at the Broad Institute and MIT. High-impact articles appeared in journals alongside research from groups at Nature Publishing Group, The Lancet, Science, and Cell Press.

The consortium has partnered with disease organizations such as the National Multiple Sclerosis Society, the Multiple Sclerosis International Federation, and regional foundations including the MS Society UK and the Canadian Institutes of Health Research. Translational collaborations link to pharmaceutical and biotech entities with programs at Roche, Novartis, Biogen Idec, Merck, and Johnson & Johnson for functional validation and therapeutic target prioritization. Cross-disciplinary alliances involve computational centers like the European Molecular Biology Laboratory and clinical trial networks associated with the WHO and national agencies such as the National Health Service.

Funding sources include grants from national funders such as the National Institutes of Health, the European Research Council, the Wellcome Trust, and the Canadian Institutes of Health Research, supplemented by contributions from charitable organizations including the Bill & Melinda Gates Foundation and disease-specific funds like the MS Society of Canada. Resource-sharing arrangements leverage biobanks like the UK Biobank, data infrastructures from the European Genome-phenome Archive, and computational resources at supercomputing centers exemplified by the Argonne National Laboratory and the Swiss National Supercomputing Centre.

Category:Genetics research organizations